Wang Lu, Yu Mingwei, Ma Yunfei, Tian Rong, Wang Xiaomin
Beijing Hospital of Traditional Chinese Medicine, Capital Medical University, No. 23, Back Road of Art Gallery, Dongcheng District, Beijing 100010, China.
Beijing Geriatric Hospital, No.118 Wenquan Road, Wenquan Town, Haidian District, Beijing 100095, China.
Evid Based Complement Alternat Med. 2022 Mar 28;2022:4133237. doi: 10.1155/2022/4133237. eCollection 2022.
Pulmonary rehabilitation (PR) has a curative effect in patients undergoing pneumonectomy for lung cancer. Nevertheless, the contribution of PR to the clinical status of patients with chronic obstructive pulmonary disease (COPD) undergoing lung resection has not been adequately elucidated. The aim of this systematic review of randomized and nonrandomized controlled trials was to appraise the impact of PR compared to conventional treatment based on postoperative clinical status in patients with lung cancer and COPD. Literature in English from PubMed, Cochrane Library, Science Citation Index, and Embase databases and in Chinese from the Chinese National Knowledge Infrastructure and the WANFANG Database was retrieved from inception to November 2021, employing the keywords "Pulmonary Neoplasms," "Chronic Obstructive Pulmonary Diseases," "Physical Therapy Modalities," and "pulmonary rehabilitation." Only studies that reported PR results were included. This review was registered in the International Prospective Register of Systematic Reviews (number: CRD42021224343). A total of nine controlled trials with 651 patients were included. Postoperative pulmonary complications (PPCs) were the primary outcome measure. PR decreased the risk of complications after surgery compared to regular treatment (odds ratio (OR) 0.21, 95% confidence interval (CI) 0.12-0.37, < 0.01). PR reduced the risk of pneumonia after surgery compared to regular treatment (OR 0.36, 95% CI 0.15-0.86, =0.02). There was a significant difference in the postoperative length of stay (mean difference -2.13 days, 95% CI -2.65 to -1.61 days, < 0.05). PR was an effective intervention that decreased PPCs in patients suffering from lung cancer and COPD. However, due to the limitations of the available data, the results should be interpreted with caution.
肺康复(PR)对接受肺癌肺切除术的患者有治疗效果。然而,PR对接受肺切除术的慢性阻塞性肺疾病(COPD)患者临床状况的贡献尚未得到充分阐明。本系统评价随机和非随机对照试验的目的是评估与基于术后临床状况的常规治疗相比,PR对肺癌和COPD患者的影响。从创刊至2021年11月,检索了PubMed、Cochrane图书馆、科学引文索引和Embase数据库中的英文文献以及中国国家知识基础设施和万方数据库中的中文文献,使用关键词“肺肿瘤”、“慢性阻塞性肺疾病”、“物理治疗方法”和“肺康复”。仅纳入报告了PR结果的研究。本评价已在国际系统评价前瞻性注册库中注册(编号:CRD42021224343)。共纳入9项对照试验,651例患者。术后肺部并发症(PPCs)是主要结局指标。与常规治疗相比,PR降低了术后并发症风险(比值比(OR)0.21,95%置信区间(CI)0.12 - 0.37,<0.01)。与常规治疗相比,PR降低了术后肺炎风险(OR 0.36,95% CI 0.15 - 0.86,=0.02)。术后住院时间有显著差异(平均差 -2.13天,95% CI -2.65至 -1.61天,<0.05)。PR是一种有效的干预措施,可降低肺癌和COPD患者的PPCs。然而,由于现有数据的局限性,对结果的解释应谨慎。